News

  • Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals The COVID-19 pandemic has created an urgent need for scientific solutions to this deadly virus. The pandemic surprised the world with a new strain of coronavirus never encountered before, which, like its predecessor, has the capacity to infect humans with severe and deadly consequences. While…
  • You get one chance to initiate a clinical trial. Botch the start-up and you’ll expend great effort correcting course and playing catch-up. The waste of money and time — commodities that are chronically scarce among the biotech and specialty pharma companies that comprise most of our customer base — can be devastating. That’s why we…
  • Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, announced that it has received FDA permission to initiate a Phase 2 clinical trial to assess the efficacy of VERU-111, a microtubule depolymerization agent, in combating COVID-19, the global pandemic disease caused…
  • Emory University and Eli Lilly have developed a strategy for studying the safety and efficacy of an anti-inflammatory drug baricitinib as a potential treatment for patients hospitalized with COVID-19. The National Institute of Allergy and Infectious Diseases (NIAID) announced Friday it has agreed to evaluate a treatment regimen of the investigational antiviral remdesivir, plus the…
  • As scientists around the world race to develop a vaccine for COVID-19, researchers at Oxford University have now pulled into the lead. The team recently began testing a vaccine candidate in people that—if effective—could possibly become available as early as September, the New York Times reported on April 27. That would be well before any other vaccine effort…
  • The coronavirus disease 2019 (COVID-19) pandemic will lead to increasing adoption of artificial intelligence, automation, and virtual clinical trials, according to a prediction presented Thursday, during a virtual session of the Community Oncology Alliance 2020 Meeting. “We really are in a place now to not lose momentum as we go through the pandemic, but in…
  • First participants dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021 NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the…
  • Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the Company’s initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI).  DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, including the potential to address…
  • At present, no drug has been proven to be safe and effective for treating COVID-19.  There are no Food and Drug Administration (FDA)-approved drugs specifically to treat patients with COVID-19. Although reports have appeared in the medical literature and the lay press claiming successful treatment of patients with COVID-19 with a variety of agents, definitive…
  • Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD), a leading cause of vision loss among people age 65 and older. The geographic atrophy form of AMD currently…